Je pagina wordt geladen…
International Consensus Statement
Inhoud in het Engels
Osler antwoordt vanuit deze bibliotheek en noemt bij elke bewering de richtlijn erachter.
Researchers and clinicians worldwide share concerns that many youngsters with attention-deficit/hyperactivity disorder (ADHD) and/or disruptive behaviour disorders (DBDs) do not receive appropriate treatment despite availability of effective therapies. At the request of Johnson and Johnson (sponsor), 11 international experts in child and adolescent psychiatry were selected by Professor Stan Kutcher (chair) to address these concerns. This paper describes the experts' consensus conclusions, including treatment practice suggestions for physicians involved in the early treatment of youngsters with ADHD (or hyperkinetic disorder, in countries preferring this classification) and/or DBDs internationally: suggested first-line treatment for ADHD without comorbidity is psychostimulant medication aided by psychosocial intervention. For ADHD with comorbid conduct disorder (CD), psychosocial intervention combined with pharmacotherapy is suggested. For primary CD, suggested first-line treatment is psychosocial intervention, with pharmacotherapy considered as an 'add-on' when aggression/impulsivity is marked and persistent. Pharmacotherapy requires careful titration; full-day coverage is the suggested goal. Regular long-term follow-up is recommended.
Gepubliceerd door European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2004. De richtlijn zelf staat bij de bron die hier is gelinkt.
Prognia vat deze richtlijn samen als naslag en voor onderwijs. Dit is geen medisch advies. Controleer altijd de officiële richtlijn en de geldende lokale protocollen voordat je ernaar handelt.
